These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2943710)

  • 1. A comparison of tumor and normal tissue levels of acidic, basic and neutral 2-nitroimidazole radiosensitizers in mice.
    Minchinton AI; Stratford MR
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1117-20. PubMed ID: 2943710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentrations achieved in human tumors after administration of misonidazole, SR-2508 and Ro 03-8799.
    Dische S; Saunders MI; Dunphy EP; Bennett MH; Des Rochers C; Stratford MR; Minchinton AI; Orchard RA
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1109-11. PubMed ID: 2943708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular uptake of misonidazole and analogues with acidic or basic functions.
    Dennis MF; Stratford MR; Wardman P; Watts ME
    Int J Radiat Biol Relat Stud Phys Chem Med; 1985 Jun; 47(6):629-43. PubMed ID: 3873433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the fate of misonidazole (RO 07-0582) and its metabolite desmethylmisonidazole (RO 05-9963), two hypoxic cell radiosensitizers: penetration properties in tumor bearing rats.
    Akel G; Canal P; Mockey E; Vandevoorde E; Laurent F; Soula G
    J Pharmacol; 1983; 14(1):67-77. PubMed ID: 6834852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours.
    Brown JM; Yu NY; Workman P
    Br J Cancer; 1979 Mar; 39(3):310-20. PubMed ID: 465300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics in mice and dogs of nitroimidazole radiosensitizers and chemosensitizers more lipophilic than misonidazole.
    White R; Workman P; Owen L
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):473-6. PubMed ID: 7107369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.
    White RA; Workman P; Brown JM
    Radiat Res; 1980 Dec; 84(3):542-61. PubMed ID: 6450431
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of binding of [3H]misonidazole and [14C]misonidazole in multicell spheroids.
    Rasey JS; Grunbaum Z; Krohn K; Nelson N; Chin L
    Radiat Res; 1985 Mar; 101(3):473-9. PubMed ID: 3983363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosensitization by a new potent nucleoside analog: 1-(1',3',4'-trihydroxy-2'-butoxy)methyl-2-nitroimidazole(RP-343).
    Murayama C; Suzuki A; Sato C; Tanabe Y; Shoji T; Miyata Y; Nishio A; Suzuki T; Sakaguchi M; Mori T
    Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):433-43. PubMed ID: 8514541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitizers and radiation dose fractionation: results and interpretations.
    Hill RP
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1049-54. PubMed ID: 2943705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic studies and neurotoxicity in tumors and brain of mice after hypoxic cell sensitizers.
    Streffer C; Tamulevicius P
    Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):571-5. PubMed ID: 8005816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trials of radiosensitizers: what should we expect?
    Brown JM
    Int J Radiat Oncol Biol Phys; 1984 Mar; 10(3):425-9. PubMed ID: 6231272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiosensitization by 2-nitroimidazole nucleoside analog RP-170: radiosensitizing effects under both intravenous and oral administration.
    Murayama C; Suzuki A; Sato C; Tanabe Y; Miyata Y; Shoji T; Suzuki T; Sakaguchi M; Mori T
    Int J Radiat Oncol Biol Phys; 1992; 22(3):557-60. PubMed ID: 1531214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorine modification of nitroazole radiosensitizers for the enhancement of sensitizing activity with lowering toxicity: a pharmacokinetic characterization.
    Kagiya VT; Nishimoto S; Ito T; Wang J; Abe M; Sasai K
    Int J Radiat Oncol Biol Phys; 1992; 22(3):601-5. PubMed ID: 1735699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic transforming potential of nitroimidazole radiosensitizers.
    Hall EJ; Hei TK
    Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1231-4. PubMed ID: 2523882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of hypoxic cell radiosensitizers: a review.
    Workman P
    Cancer Clin Trials; 1980; 3(3):237-51. PubMed ID: 7438321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic studies using multiple administration of RO 03-8799, a 2-nitroimidazole radiosensitizer.
    Stratford MR; Minchinton AI; Hill SA; McNally NJ; Williams MV
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):469-71. PubMed ID: 7107368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additivity of radiosensitization by the combination of SR 2508 (etanidazole) and Ro 03-8799 (pimonidazole) in a murine tumor system.
    Honess DJ; Wasserman TH; Workman P; Ward R; Bleehen NM
    Int J Radiat Oncol Biol Phys; 1988 Sep; 15(3):671-5. PubMed ID: 2971028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Present status of radiation sensitizers--hypoxic cell radiosensitizer].
    Murayama C; Mori T
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2135-41. PubMed ID: 2660744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxic cell radiosensitizers: expectations and progress in drug development.
    Coleman CN
    Int J Radiat Oncol Biol Phys; 1985 Feb; 11(2):323-9. PubMed ID: 3156109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.